Starting on:
Feb 26, 2025
Ending on:
Feb 26, 2025
Moderator(s):
Venue:
KUTRRH
Max Credits:
3 Points
Provider:
Kenyatta University Teaching and Referral Hospital
Claim Points
Feb 26, 2025
Ending on:
Feb 26, 2025
Moderator(s):
KUTRRH
Max Credits:
3 Points
Provider:
Kenyatta University Teaching and Referral Hospital
Claim Points
Undescended testis
Starting on:
Feb 26, 2025
Feb 26, 2025
Ending on:
Feb 26, 2025
Feb 26, 2025
Venue:
KUTRRH
KUTRRH
Description
Introduction Definition: Cryptorchidism is the failure of one or both testes to descend into the scrotum, a condition with implications for fertility and malignancy. Epidemiology: Full-term neonates: 1-4% prevalence. Preterm neonates: ~30% prevalence. Clinical Significance: Early diagnosis and intervention are critical for optimizing outcomes.
Objectives
Management of UDT Recommended by AAP (1996) & EAU (2012): Orchiopexy for healthy males by 12-18 months of age. Early Intervention: 18% by 1 year; 43% by 2 years. Delayed treatment more common in Black & Hispanic boys. Symptomatic hernia may warrant earlier surgery. Benefits of Early Treatment: Reduces malignancy, infertility risks, and torsion. Facilitates testicular examination & endocrine function. Creates normal-appearing scrotum. Hormonal Treatment for UDT
Controversial Use: Hormonal therapy (Buserelin, hCG) for UDT. European Use: Buserelin (LHRH agonist) shows success in cases distal to external inguinal ring (60% success). Combined Therapy: Buserelin + hCG: 60% success, with 40% requiring orchiopexy. Fertility Impact: Clinical trials suggest improved fertility with neoadjuvant LHRH therapy.
Presenters
-
Dr.
Onle Yusuf
Dr.